Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis

Title
Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis
Author(s)
최혜덕신완균[신완균]
Keywords
TYPE-2 DIABETES-MELLITUS; COMBINED HYPERLIPIDEMIA; FENOFIBRIC ACID; MIXED DYSLIPIDEMIA; DOUBLE-BLIND; PLUS FENOFIBRATE; CLINICAL-TRIALS; SIMVASTATIN; THERAPY; GEMFIBROZIL
Issue Date
201401
Publisher
INFORMA HEALTHCARE
Citation
CURRENT MEDICAL RESEARCH AND OPINION, v.30, no.1, pp.1 - 10
Abstract
Background: Dyslipidemia is a major risk factor for cardiovascular disease and is treated with many effective lipid-lowering agents. Statins are often used alone or in combination with fibrates. Combination therapy is more effective due to their comparative actions, but the increased incidence of side effects should be considered carefully. Research design and methods: A meta-analysis of published data was conducted to compare the safety and efficacy of statins alone versus statins plus fibrates in patients with dyslipidemia. In total, nine articles were assessed for efficacy analysis and ten articles were assessed for safety analysis. Results: In the efficacy analysis, a combination of statins and fibrates provided significantly greater reductions in total cholesterol (SE = 0.430; 95% CI 0.315-0.545), LDL cholesterol (SE = 0.438; 95% CI 0.321-0.555) and triglycerides (SE = 0.747; 95% CI 0.618-0.876), and a significantly greater increase in HDL cholesterol (SE = 0.594; 95% CI 0.473-0.715) than treatment with statins alone. In the safety analysis, treatment with statins alone was associated with a significant reduction in the numbers of total adverse events (RR = 0.665; 95% CI 0.539-0.819), liver-related adverse events (RR = 0.396; 95% CI 0.206-0.760) and kidney-related adverse events (RR = 0.146; 95% CI 0.075-0.285). Conclusion: We suggest that treatment with statins plus fibrates provides clinical benefits over treatment with statins alone but increased risks, especially of hepatic or renal side effects, should be monitored carefully.
URI
http://hdl.handle.net/YU.REPOSITORY/33467http://dx.doi.org/10.1185/03007995.2013.842165
ISSN
0300-7995
Appears in Collections:
약학대학 > 약학부 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE